Elias Jabbour, MD

Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Articles

Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data

July 18th 2024

A medical expert elaborates on the therapeutic role of brexucabtagene autoleucel in the management of relapsed or refractory B-cell acute lymphoblastic leukemia.

Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives

July 11th 2024

The panel examines the current positioning of CAR T-cell therapy within the treatment paradigm for Relapsed / Refractory Acute Lymphoblastic Leukemia, considering the distinctions between Philadelphia chromosome-positive and negative patients.

Overview of Available Treatment Options in R/R B-cell ALL

July 11th 2024

The panelists explore therapeutic strategies for adult patients diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia.

Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment

July 4th 2024

Medical experts outline the typical timeline for CAR T-cell therapy, encompassing the stages from initial cell collection through manufacturing to final patient infusion.

Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL

July 4th 2024

Key opinion leaders succinctly compare the dosing and lymphodepletion protocols for Brexucabtagene autoleucel, Tisagenlecleucel, and Obecabtagene autoleucel.

CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel

June 27th 2024

Dr. Lori Muffly explains the general mechanism of action in CAR T-cell therapy and compares the distinct features of Brexucabtagene autoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtagene autoleucel (Obe-cel).

Overview of CAR T-cell Therapies in R/R B-cell ALL

June 27th 2024

Evandro D. Bezerra, MD, provides an overview of current CAR T-cell therapies for relapsed/refractory B-cell acute lymphoblastic leukemia and explores emerging CAR T products under investigation.

Dr Jabbour on the Results of the PhALLCON Trial in Newly Diagnosed Ph+ ALL

May 1st 2024

Elias Jabbour, MD, discusses outcomes from the phase 3 PhALLCON trial in patients with Ph-positive acute lymphoblastic leukemia.

Dr Ignatz-Hoover on the Evolving Use of Blinatumomab in ALL

April 24th 2024

James Ignatz-Hoover, MD, PhD, discusses the implications of utilizing blinatumomab to treat acute lymphoblastic leukemia.

FDA Approval Insights: Ponatinib in Ph+ ALL

April 8th 2024

Dr Jabbour expands on the FDA approval of ponatinib for patients with Ph-positive ALL, the agent’s mechanism of action, and data from the PhALLCON trial.

Dr Jabbour on the Significance of the FDA Approval of Ponatinib Plus Chemo for PH+ ALL

March 20th 2024

Elias Jabbour, MD, discusses the FDA approval of ponatinib plus chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia.

Acute Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Following the ASCO 2023 and EHA 2023 Annual Meetings, experts discuss important updates in acute myeloid leukemia.

Acute Lymphoblastic Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Shared insight from key opinion leaders on clinical trial data in acute lymphoblastic leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

Chronic Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Expert perspectives on key data in chronic myeloid leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

Dr Jabbour on the Efficacy of Ponatinib in Newly Diagnosed Ph+ ALL

June 9th 2023

Elias Jabbour, MD, discusses efficacy data from the phase 3 PhALLCON trial of ponatinib plus reduced-intensity chemotherapy vs imatinib plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Gaining Ground in Gynecologic and Hematologic Cancers at ASCO 2023: Drs Herrera, Westin, and Jabbour

June 5th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting

February 14th 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

ASH 2022: Recent Advances in Chronic Myeloid Leukemia

February 14th 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape

February 14th 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Dr. Jabbour on the Evaluation of Olverembatinib in Ponatinib-Resistant CML and Ph+ ALL

December 23rd 2022

Elias Jabbour, MD, discusses the evaluation of olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.